AHA announces late-breaking science lineup to be presented at 2022 Scientific Sessions
Click Here to Manage Email Alerts
The American Heart Association Scientific Sessions will be held live in Chicago and can be attended virtually Nov. 5 to 7, and will feature nine late-breaking science sessions over 3 days.
The AHA announced the following late-breaking science lineup for the annual meeting.
Late-Breaking Science 1: The Main Event: Changing Clinical Practice —
- effectiveness of torsemide compared with furosemide in HF: the TRANSFORM-HF trial;
- chlorthalidone compared with hydrochlorothiazide for prevention of CV events in patients with hypertension: the DCP trial; and
- pemafibrate (Kowa) for the reduction of triglycerides for the prevention of CVD: the PROMINENT trial.
Late-Breaking Science 2: Breakthrough Strategies in the HF Journey —
- the first-in-human in vivo Crispr/Cas9 editing of the Ttr gene by Ntla-2001 in patients with transthyretin amyloidosis with cardiomyopathy;
- the trial of a patient-risk based health system intervention for acute HF: the COACH trial;
- early findings of the patient-reported outcome measurement in HF clinic: the PRO-HF trial; and
- a randomized trial of IV ferric derisomaltose in HF with reduced ejection fraction: the IRONMAN trial.
Late-Breaking Science 3: High Impact Trials in Intervention and Surgery —
- the 15-year outcomes of radial artery compared with right internal thoracic artery or with saphenous vein grafting: the RAPCO trial;
- steroids for the reduction of systemic inflammation after infant heart surgery: the Stress trial;
- effect of tongxinluo in patients with acute MI: the CTS-AMI trial; and
- extracorporeal membrane oxygenation for cardiogenic shock: the ECMO-CS trial.
Late-Breaking Science 4: Mindful Disruption of Chronic Hypertension Management —
- effectiveness of a village doctor-led implementation strategy for CVD in patients with hypertension: the CRHCP trial;
- BP and patient-reported outcomes in a trial to reduce inequities in care of hypertension: the Rich Life Project;
- adapted mindfulness training in participants with high in-office BP: the MB-BP Study; and
- efficacy and safety of a quadruple ultra-low-dose treatment for hypertension: the QUARTET USA trial.
Late-Breaking Science 5: Changing How we Prevent Cardiovascular and Renal Disease —
- efficacy of secondary prevention with combination statin and eicosapentaenoic acid: the RESPECT-EPA trial;
- lipoprotein(a) reduction with small interfering RNA: the OCEAN(a)-DOSE trial;
- empagliflozin and CV outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial; and
- low-dose statin compared with placebo and six dietary supplements on lipid and inflammatory biomarkers: the SPORT trial.
Late-Breaking Science 6: Drugs and Strategies in ACS and Revascularization —
- bivalirudin with post-PCI high-dose infusion compared with heparin monotherapy during primary PCI in STEMI: the BRIGHT-4 trial;
- the efficacy and safety of indobufen compared with aspirin after coronary drug-eluting stent implantation: the OPTION trial;
- a precision care strategy compared with usual testing to guide management of stable patients with suspected CAD: the PRECISE trial; and
- an interim follow-up report from ISCHEMIA-EXTENDed.
Late-Breaking Science 7: Preventing Limb Loss Through Vascular Interventions and Venous Therapies —
- best endovascular compared with best surgical therapy for patients with chronic limb threatening ischemia: the BEST-CLI trial;
- a quality of life analysis of patients in the BEST-CLI trial;
- rivaroxaban (Xarelto, Janssen/Bayer) to reduce risk for major venous and arterial thrombotic events, hospitalization and death in outpatients with COVID-19: the PREVENT-HD trial; and
- A multicenter trial of a universal electronic health record-based venous thromboembolism risk assessment model integrated for clinical decision support for prevention of thromboembolism in hospitalized patients: the IMPROVE trial.
Late-Breaking Science 8: Treating Atrial and Supraventricular Arrhythmias —
- “first-line” rhythm therapy for atrial fibrillation progression: the PROGRESSIVE-AF trial;
- self-administered etripamil (Milestone Pharmaceuticals) for termination of spontaneous paroxysmal supraventricular tachycardia: the RAPID trial;
- efficacy and safety of botulinum toxin type A for the prevention of postoperative AF in patients who underwent cardiac surgery: the phase 2 NOVA trial; and
- a trial to evaluate a shared decision-making pathway for AF stroke prevention: the ENHANCE-AF trial.
Late-Breaking Science 9: Resistant Hypertension: A Pressure Cooker —
- top-line results of the first-in-class aminopeptidase A inhibitor firibastat (Quantum Genomics) for resistant hypertension: the FRESH trial;
- sustained BP lowering with a dual endothelin receptor antagonist, aprocitentan (Idorsia), for resistant hypertension: the PRECISION trial;
- results from the phase 2 trial evaluating the efficacy and safety of baxdrostat (CinCor) in patients with resistant hypertension: the BrigHTN trial; and
- 6-month effects of radiofrequency renal denervation on BP in patients already taking antihypertensives: SPYRAL HTN-ON Med.
Healio | Cardiology Today will be on-site in Chicago to report the latest news from the AHA Scientific Sessions, with physician perspective, researcher interviews and more. Follow our breaking updates here and by following @CardiologyToday on Twitter.
Click Here to Manage Email Alerts